Skip to main content
HR 2653 117th Congress House Taxation Aging Business expenses Business investment and capital Cardiovascular and respiratory health Community life and organization Congressional oversight Drug safety, medical device, and laboratory regulation Economic development Emergency medical services and trauma care Government studies and investigations Health technology, devices, supplies Housing and community development funding Immunology and vaccination Income tax credits Income tax deductions Industrial facilities Infectious and parasitic diseases Manufacturing Medical research

MMEDS Act of 2021

Introduced: April 19, 2021 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 20, 2021
Referred to the Subcommittee on Health.
Apr 19, 2021
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 19, 2021
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medical Manufacturing, Economic Development, and Sustainability Act of 2021 or the MMEDS Act of 2021

This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical manufacturers. The bill increases the credit rate for minority businesses.

What's happening now April 20, 2021

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 1203 Related bill MMEDS Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Cosponsors 4
All 4 Democratic 2 Republican 2
R
Diaz-Balart, Mario
Florida · Apr 19, 2021
 D
Gallego, Ruben
Arizona · Apr 19, 2021
 R
Salazar, Maria Elvira
Florida · Apr 19, 2021
 D
Soto, Darren
Florida · Apr 19, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2653: MMEDS Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2653/
MLA
"H.R. 2653: MMEDS Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2653/.
Bluebook (legal)
H.R. 2653, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2653/.
Markdown link
[H.R. 2653: MMEDS Act of 2021](https://openamerica.io/bill/117-HR-2653/)
Report a problem